Slide 1: Niagen Bioscience, Inc. Earnings Presentation First Quarter 2025
Niagen Bioscience, Inc. Earnings Presentation First Quarter 2025 Nasdaq: NAGE | May 7, 2025
Slide 2: Safe Harbor Statement
This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Slide 3: Q1 2025 & Recent Highlights
Q1 2025 & Recent Highlights • Total company and Tru Niagen® net sales: $30.5 million and $21.5 million, up 38%, and 24% YoY, respectively. • Total Niagen® ingredient sales: $8.0 million, up 95% YoY. • Gross margin: 63.4%, up 270 basis points YoY. • Sales and marketing expense as a percentage of net
Slide 4: Leadership Team
Leadership Team Rob Fried Ozan Pamir Chief Executive Officer Chief Financial Officer E-commerce & Over a decade of capital entertainment industry markets and public company executive experience in the life sciences industry Savoy Pictures, Columbia Pictures, Fried Films, FeeIn, CFA Charterholder WHN
Slide 5: Financial Highlights
Financial Highlights The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019)
Slide 6: Q1 2025 Net Sales Mix
Q1 2025 Net Sales Mix Q1 2025 Q1 2024 Watson's & Other B2B Watson's & Other B2B 16% 20% E-Commerce 58% E-Commerce 55% Food-grade Niagen® Food-grade Niagen® $30.5 MM 23% $22.2 MM 19% Pharmaceutical-grade Niagen® Analytical Reference 3% Standards & Services 3% Analytical Reference Standards & Services
Slide 7: Q1 2025 Net Sales
Q1 2025 Net Sales Q1 2025 Net Sales Growth Rates ($ in millions) YoY % (vs Q1 2024) E-Commerce 16.8 +31% $21.5 Watson's & Other B2B 4.7 +3% Food-grade Niagen® 7.0 +71% Pharmaceutical-grade Niagen® 1.0 N/A Analytical Reference Standards 0.8 & Services +14% Other Ingredients 0.2 0% Total +38% Total sa
Slide 8: 2024 – 2025 Net Sales Summary
2024 – 2025 Net Sales Summary ($ in millions) 2025 2024 Description Q1 Q1 Q2 Q3 Q4 FY Ecommerce 16.8 12.9 13.0 14.8 17.3 58.0 Watsons & Other B2B 4.7 4.5 5.6 3.3 5.4 18.8 Total TRU NIAGEN 21.5 17.4 18.6 18.1 22.7 76.8 Food-grade NIAGEN 7.0 4.1 3.1 5.8 4.5 17.5 Pharmaceutical-grade NIAGEN 1.0 0.0 0.0
Slide 9: Q1 2025 vs Q1 2024 Key P&L Metrics
Q1 2025 vs Q1 2024 Key P&L Metrics (in thousands) Q1 2025 Q1 2024 Notes Tru Niagen® and Niagen® ingredient business up 24% and 95%, respectively, driven by strong Ecommerce performance, higher demand from key food- Net Sales $30,481 $22,153 grade Niagen® partners and the ramp up of pharmaceutical-gr
Slide 10: Adjusted EBITDA Summary
Adjusted EBITDA Summary Niagen Bioscience, Inc. and Subsidiaries Reconciliation of Non-GAAP Finanical Measures (In thousands) Three Months Three Months Ended Ended Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Net income (loss), as reported $ (492) $ (15) $ 1,878 $ 7,179 $ 5,063 Adjustments Interest (inco
Slide 11: Q1 2025 Operating Income (Loss) vs Q1 2024
Q1 2025 Operating Income (Loss) vs Q1 2024 -$1.7 MM +$7.2 MM (in millions) 6.0 5.0 0.5 4.8 0.8 4.0 0.8 3.0 5.1 2.0 1.0 — (1.0) (0.7) (0.1) (0.2) (2.0) (1.4) (3.0) Q1 2024 Legal Equity Comp Sales & Volume Gross Margin Research and Other G+A (1) Q1 2025 Operating Loss (G+A) Marketing Improvement Devel
Slide 12: Quarterly Balance Sheet Highlights
Quarterly Balance Sheet Highlights (in thousands) 3/31/24 6/30/24 9/30/24 12/31/24 3/31/25 Key Drivers (Q4 2024 vs Q1 2025) Up $11.0 million largely driven by net income and proceeds from Cash $27,565 $27,885 $32,398 $44,660 $55,616 stock option exercises Up $2.0 million as inventory levels were sca
Slide 13: Cash Flow Highlights
Cash Flow Highlights Three Months Three Months Ended FY Ended (in thousands) 2024 3/31/24 6/30/24 9/30/24 12/31/2024 3/31/25 Net Income (Loss) $(492) $(15) $1,878 $7,179 $8,550 $5,063 Working Capital (643) (1,837) 1,235 5,111 3,866 2,681 Cash From / (Used for) Operations 295 (264) 3,495 8,583 12,109
Slide 14: 2025 Financial Outlook
2025 Financial Outlook (in thousands) 2024 Actual 2025 Full Year Outlook Key Drivers • Includes growth from e-commerce business and recurring revenues from established partnerships. Between 20%-25% growth YoY Net Sales $99,597 • Includes revenues from new partnerships, and revenue (Previously approx
Slide 15: The Science
The Science 15 The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019)
Slide 16: Scientific Advisory Board
Scientific Advisory Board 16
Slide 17: Clinical Studies on Oral Niagen® in Multiple Health Areas
Clinical Studies on Oral Niagen® in Multiple Health Areas Note: Highlighted achievements in duration, participation, and dosage only consider peer-reviewed, published studies. Status of clinical studies presented as of April 21, 2025. 17
Slide 18: Contact Info
Contact Info: Ben Shamsian Lytham Partners T: +1(646) 829-9701 Shamsian@LythamPartners.com www.NiagenBioscience.com Where to purchase Tru Niagen® TruNiagen.com Find Health Clinics Offering Niagen® Plus NiagenPlus.com The information contained in this documents is confidential, privileged and only fo